Search results for "Rejection"

showing 10 items of 169 documents

Donor/recipient algorithm for management of the middle hepatic vein in right graft live donor liver transplantation

2010

Abstract Background The aim of this study was to delineate an algorithm for donor and recipient criteria and middle hepatic vein (MHV) management in right-graft live-donor liver transplantation (LDLT) on the basis of computerized 3-dimensional computed tomographic image analysis. Methods Data on 94 consecutive right-graft LDLTs were prospectively collected. Graft and remnant data for the first 23 cases were retrospectively evaluated by means of 3-dimensional computed tomographic reconstructions, and on the basis of that preliminary series, a graft selection algorithm using 3 parameters—hepatic vein dominance classification, graft and remnant graft volume/body weight ratios, and congestion v…

Graft RejectionMalemedicine.medical_specialtyTissue and Organ ProcurementLive donormedicine.medical_treatmentHepatic VeinsLiver transplantationliverBody weightRisk AssessmentPreoperative careComputed tomographicCohort StudiesImaging Three-DimensionalPostoperative ComplicationsPreoperative CareLiving DonorsmedicineGraft selectionHepatectomyHumansProspective StudiesAnalysis of VarianceSmall for size syndromebusiness.industryPatient SelectionGraft SurvivalGeneral MedicineLiver TransplantationSurgeryTreatment Outcomesurgical procedures operativeMathematikFemaleSurgeryHepatectomyTomography X-Ray ComputedbusinessAlgorithmAlgorithmsFollow-Up StudiesLiver CirculationThe American Journal of Surgery
researchProduct

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System : success or waste of organs? The Eurotransplant 15-year all-centr…

2016

Item does not contain fulltext BACKGROUND: In the Eurotransplant Kidney Allocation System (ETKAS), transplant candidates can be considered for high-urgency (HU) status in case of life-threatening inability to undergo renal replacement therapy. Data on the outcomes of HU transplantation are sparse and the benefit is controversial. METHODS: We systematically analysed data from 898 ET HU kidney transplant recipients from 61 transplant centres between 1996 and 2010 and investigated the 5-year patient and graft outcomes and differences between relevant subgroups. RESULTS: Kidney recipients with an HU status were younger (median 43 versus 55 years) and spent less time on the waiting list compared…

Graft RejectionMalemedicine.medical_treatmentMedizin030232 urology & nephrologygraft survival030230 surgery0302 clinical medicineSurveys and QuestionnairesDIALYSISYoung adultChildKidney transplantationCANDIDATESKidneyMiddle AgedPrognosis3. Good healthEuropeMulticenter Studymedicine.anatomical_structureNephrologyChild PreschoolFemaleHemodialysisAdultReoperationmedicine.medical_specialtykidneyTissue and Organ ProcurementAdolescentWaiting ListsDonor SelectionResource AllocationYoung Adult03 medical and health sciencespatient survivalInternal medicinemedicineJournal ArticleHumansComparative StudyRenal replacement therapyDialysisAgedbusiness.industryDonor selectionInfant NewbornInfantmedicine.diseaseKidney TransplantationSurgeryTransplantationhigh-urgencyPRIORITYSURVIVAL BENEFITrenalHuman medicineRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]businessWAITING TIMEtransplantationNephrology, dialysis, transplantation
researchProduct

Hepatitis C virus re-infection: new perspectives

2006

Hepatitis C virus (HCV) re-infection of the liver graft has been recognized to be one of the most important factors that determines prognosis and outcome after liver transplantation in HCV-positive patients. Graft loss due to recurrent HCV re-cirrhosis and subsequent hepatic decompensation, which is the predominant cause of death among transplant recipients, reflects the prognostic significance of HCV re-infection. Despite better overall outcome after liver transplantation, the prognosis of HCV-infected patients has not improved during the last two decades. Recent data suggest that increased liver donor age and intensified immunosuppression of transplant patients are the most important cont…

Graft RejectionOncologymedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepatitis C virusHepacivirusHepacivirusLiver transplantationmedicine.disease_causechemistry.chemical_compoundRecurrenceInternal medicinemedicineHumansCause of deathTransplantationbiologybusiness.industryRibavirinImmunosuppressionHepatitis C Chronicmedicine.diseasebiology.organism_classificationLiver TransplantationTransplantationchemistryImmunologybusinessClinical Transplantation
researchProduct

Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?

2006

Objectives: To assess the functional effects of multipotent adult progenitor cells (MAPCs) transplanted in a rat model of chronic myocardial infarction. Methods: Forty-four rats underwent coronary ligation and, 14 days later, were randomly allocated to receive in-scar injections (5×106 cells/150 μL) of green fluorescent protein (eGFP)-transduced allogeneic MAPCs ( n =25) or culture medium (controls, n =19). Nine of the MAPC-treated hearts were employed for functional studies while the remaining 16 received cells co-labeled with Resovist™ and were only used for serial histological assessments. Left ventricular (LV) function was assessed echocardiographically before transplantation and 1 mont…

Graft RejectionPathologymedicine.medical_specialtyEndotheliumPhysiologyMyocardial InfarctionBone Marrow CellsRats Sprague-DawleyPhysiology (medical)MedicineAnimalsMyocardial infarctionTreatment FailureProgenitor cellbusiness.industryMultipotent Stem CellsMyocardiummedicine.diseaseMyocardial ContractionRatsTransplantationmedicine.anatomical_structureMultipotent Stem CellModels AnimalImmunohistochemistryFemaleBone marrowStem cellCardiology and Cardiovascular MedicinebusinessCardiovascular research
researchProduct

Pivotal Advance: Up-regulation of acetylcholine synthesis and paracrine cholinergic signaling in intravascular transplant leukocytes during rejection…

2009

Abstract A new role and source of the old mediator acetylcholine is described, which is produced by graft monocytes and attenuates monocytic ATP-signaling. During acute rejection, large numbers of leukocytes accumulate in the blood vessels of experimental renal allografts. About 70% of them are activated, cytotoxic monocytes that appear to be involved in allograft destruction. ACh exerts anti-inflammatory effects upon monocytes/macrophages and has been proposed to be a key player in neuroimmunological interactions. Its short half-life, however, makes it unlikely that neuronal ACh affects blood leukocytes. Renal transplantation was performed in the allogeneic DA to LEW and in the isogeneic L…

Graft RejectionPathologymedicine.medical_specialtyIsograftImmunologyBiologyReceptors NicotinicParacrine signallingAdenosine TriphosphateIn vivoParacrine CommunicationmedicineImmunology and AllergyCytotoxic T cellAnimalsTransplantation HomologousLymphocytesCation Transport ProteinsMonocyteCell BiologyKidney TransplantationAcetylcholineRatsUp-RegulationTransplantationTransplantation Isogeneicmedicine.anatomical_structureRats Inbred LewImmunohistochemistryCholinergicSignal TransductionJournal of leukocyte biology
researchProduct

Effects of leflunomide on immune responses and models of inflammation.

1993

Leflunomide is an antiphlogistic and immunomodulating agent that has been shown to be effective in preventing and healing autoimmune disorders and reactions leading to organ graft rejection. From our preliminary clinical data [4], we now have hopes that these effects, observed in experimental animals, can truly be transferred to humans. Although we are far from understanding the mode of action of leflunomide, we are slowly gathering some insight. A good many of the immunosuppressive effects of leflunomide can be attributed to the antagonistic effects it has on responses to many cytokines, most likely through receptor expression and signal transduction (tyrosine kinase inhibition). The inhib…

Graft RejectionReceptor expressionImmunologyDrug Evaluation PreclinicalAutoimmune Diseaseschemistry.chemical_compoundMiceImmune systemMedicineAnimalsHumansLeflunomideInflammationImmunity Cellularbusiness.industryAnti-Inflammatory Agents Non-SteroidalAutoantibodyGeneral MedicineIsoxazolesProtein-Tyrosine KinasesRatsDisease Models AnimalchemistryImmunologyAntibody FormationCytokinesSignal transductionbusinessTyrosine kinaseImmunomodulating AgentHistamineImmunosuppressive AgentsLeflunomidemedicine.drugSpringer seminars in immunopathology
researchProduct

Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

2021

Heart retransplantation (ReHT) is controversial in the current era. The aim of this study was to describe and analyze the results of ReHT in Spain. Methods We performed a retrospective cohort analysis from the Spanish Heart Transplant Registry from 1984 to 2018. Data were collected on donors, recipients, surgical procedure characteristics, immunosuppression, and survival. The main outcome was posttransplant all-cause mortality or need for ReHT. We studied differences in survival according to indication for ReHT, the time interval between transplants and era of ReHT. Results A total of 7592 heart transplants (HT) and 173 (2.3%) ReHT were studied (median age, 52.0 and 55.0 years, respectively…

Graft RejectionReoperationmedicine.medical_specialtyTrasplante cardiacoSurvivalmedicine.medical_treatmentRetrasplante cardiacoEnfermedad cardiovascularCardiac allograft vasculopathyCold Ischemia TimeHeart retransplantation Heart transplant Retrasplante cardiaco Supervivencia Survival Trasplante cardiacoCirugíaInternal medicinemedicineHumansRegistriesTrasplante de corazónBalloon pumpPrimary graft failureRetrospective StudiesMechanical ventilationHeart transplantsSupervivenciabusiness.industryAnálisis de datosImmunosuppressionRetrospective cohort studyGeneral MedicineMiddle AgedSpainHeart retransplantationCardiologyHeart TransplantationHeart transplantbusiness
researchProduct

Organ xenografting between rodents: an evolutionary perspective

1994

Rejection times of heart xenografts in several donor-recipient combinations including the guinea pig, rat, hamster, and mouse are examined in light of the paleontological history of rodents and the resulting phylogenetic distances between taxa. This multidisciplinary review at the molecular, chromosomal and morphological levels suggests that xenograft rejection time is inversely proportional to the time divergence or phylogenetic distance, and that the binomial terminology concordant/discordant does not reflect the amplitude of phylogenetic distances.

Graft RejectionTransplantationPhylogenetic treeXenotransplantationmedicine.medical_treatmentTransplantation HeterologousHamsterZoologyRodentiaBiologyGuinea pigMultidisciplinary reviewPhylogenetic distanceTaxonTransplant surgeryEvolutionary biologymedicineAnimalsHeart TransplantationHumansPhylogenyTransplant International
researchProduct

The effect of ischemia/reperfusion on the kidney graft.

2014

Ischemia/reperfusion injury is an unavoidable companion after kidney transplantation and influences short-term as well as long-term graft outcome. Clinically ischemia/reperfusion injury is associated with delayed graft function, graft rejection, and chronic graft dysfunction. Ischemia/reperfusion affects many regulatory systems at the cellular level as well as in the renal tissue that eventually result in a distinct inflammatory reaction of the kidney graft.Underlying factors include energy metabolism, cellular changes of the mitochondria and cellular membranes, initiation of different forms of cell death-like apoptosis and necrosis together with a recently discovered mixed form termed necr…

Graft RejectionTransplantationmedicine.medical_specialtyKidneyGraft dysfunctionGraft rejectionbusiness.industryT-LymphocytesIschemiamedicine.diseaseKidney TransplantationDelayed Graft FunctionImmunity InnateSurgerysurgical procedures operativemedicine.anatomical_structureImmunityReperfusion InjurymedicineImmunology and AllergyAnimalsHumansbusinessReperfusion injuryKidney transplantationCurrent opinion in organ transplantation
researchProduct

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

2013

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolim…

Graft Rejectionmedicine.medical_specialtyCYP3A5ATP Binding Cassette Transporter Subfamily BCYP3A4Genotypemedicine.medical_treatmentPharmacologyLiver transplantationBioinformaticsOrgan transplantationTacrolimusCalcineurin inhibitorMedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsDosingATP Binding Cassette Transporter Subfamily B Member 1Topic HighlightKidney transplantLiver transplantKidney transplantationBiotransformationPolymorphism Geneticbusiness.industryPharmacogeneticGraft SurvivalGastroenterologyABCB1General Medicinemedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationSingle nucleotide polymorphismTransplantationsurgical procedures operativePhenotypeTreatment OutcomePharmacogeneticsTacrolimuSettore BIO/14 - FarmacologiaPersonalized medicinebusinessPharmacogeneticsImmunosuppressive Agents
researchProduct